AMB-104
AML and solid tumors
DiscoveryActive
Key Facts
About AmMax Bio
AmMax Bio is a private, clinical-stage biotech leveraging a clinically validated anti-CSF1R antibody platform to build a differentiated oncology pipeline. Its lead asset, AMB-066, is a monoclonal antibody in a Phase 2 proof-of-concept study for colorectal cancer minimal residual disease (CRC MRD), supported by a safety profile established across six prior clinical trials. The company, founded by an experienced entrepreneur with a successful track record and in partnership with Amgen, is targeting significant commercial opportunities in oncology with a pipeline that also includes an ADC and another mAb for various solid tumors and hematologic malignancies.
View full company profile